Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical evidence without systematic review methodology.
What was done
This narrative review synthesized evidence on the pharmacokinetics, pharmacodynamics, efficacy, and hemodynamic safety of three phosphodiesterase type 5 (PDE5) inhibitors (sildenafil citrate, tadalafil, and vardenafil hydrochloride) in men with erectile dysfunction, including those with comorbid cardiovascular disease and other high-risk conditions.
What was found
The abstract reports no numerical values, confidence intervals, or quantitative effect sizes. It states qualitatively that therapeutic doses of PDE5 inhibitors produce only mild and transient changes in mean systolic and diastolic blood pressure and heart rate in healthy men and in those with ischemic heart disease or chronic stable angina. Favorable safety and efficacy were noted in men with ischemic cardiovascular disease, men taking antihypertensive medications, men with diabetes, and men who have undergone nerve-sparing retropubic radical prostatectomy.
Why it matters
The paper outlines clinical considerations for choosing among three PDE5 inhibitors, highlighting their overall safety in patients with cardiovascular and metabolic comorbidities.
Limits
The review relies on narrative synthesis rather than a systematic methodology, and the abstract provides no specific study count, sample sizes, quantitative outcomes, or incidence rates of adverse events.
Cited by
- supports Tadalafil causes vasodilation that slightly lowers blood pressure.